Logo image of AJ91.DE

DOCCHECK AG (AJ91.DE) Stock Fundamental Analysis

FRA:AJ91 - Deutsche Boerse Ag - DE000A1A6WE6 - Common Stock - Currency: EUR

11.9  -0.1 (-0.83%)

Fundamental Rating

6

Taking everything into account, AJ91 scores 6 out of 10 in our fundamental rating. AJ91 was compared to 10 industry peers in the Health Care Technology industry. AJ91 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AJ91 has a correct valuation and a medium growth rate. Finally AJ91 also has an excellent dividend rating. This makes AJ91 very considerable for dividend investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year AJ91 was profitable.
AJ91 had a positive operating cash flow in the past year.
In the past 5 years AJ91 has always been profitable.
In the past 5 years AJ91 always reported a positive cash flow from operatings.
AJ91.DE Yearly Net Income VS EBIT VS OCF VS FCFAJ91.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

1.2 Ratios

AJ91 has a Return On Assets of 9.09%. This is comparable to the rest of the industry: AJ91 outperforms 60.00% of its industry peers.
AJ91 has a Return On Equity (13.18%) which is in line with its industry peers.
With a decent Return On Invested Capital value of 8.86%, AJ91 is doing good in the industry, outperforming 70.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AJ91 is in line with the industry average of 9.32%.
Industry RankSector Rank
ROA 9.09%
ROE 13.18%
ROIC 8.86%
ROA(3y)7.87%
ROA(5y)12.82%
ROE(3y)11.84%
ROE(5y)19.17%
ROIC(3y)9.31%
ROIC(5y)15.17%
AJ91.DE Yearly ROA, ROE, ROICAJ91.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

AJ91 has a Profit Margin (9.82%) which is in line with its industry peers.
AJ91's Profit Margin has been stable in the last couple of years.
The Operating Margin of AJ91 (12.33%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of AJ91 has declined.
The Gross Margin of AJ91 (79.18%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of AJ91 has remained more or less at the same level.
Industry RankSector Rank
OM 12.33%
PM (TTM) 9.82%
GM 79.18%
OM growth 3Y-13.6%
OM growth 5Y-2.73%
PM growth 3Y-9.54%
PM growth 5Y0.26%
GM growth 3Y11.03%
GM growth 5Y-0.26%
AJ91.DE Yearly Profit, Operating, Gross MarginsAJ91.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

AJ91 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for AJ91 remains at a similar level compared to 1 year ago.
Compared to 5 years ago, AJ91 has more shares outstanding
Compared to 1 year ago, AJ91 has an improved debt to assets ratio.
AJ91.DE Yearly Shares OutstandingAJ91.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AJ91.DE Yearly Total Debt VS Total AssetsAJ91.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

AJ91 has an Altman-Z score of 4.34. This indicates that AJ91 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AJ91 (4.34) is better than 70.00% of its industry peers.
There is no outstanding debt for AJ91. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.34
ROIC/WACC1.3
WACC6.81%
AJ91.DE Yearly LT Debt VS Equity VS FCFAJ91.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 2.74 indicates that AJ91 has no problem at all paying its short term obligations.
AJ91 has a Current ratio of 2.74. This is amongst the best in the industry. AJ91 outperforms 90.00% of its industry peers.
A Quick Ratio of 2.50 indicates that AJ91 has no problem at all paying its short term obligations.
The Quick ratio of AJ91 (2.50) is better than 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.5
AJ91.DE Yearly Current Assets VS Current LiabilitesAJ91.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 133.18% over the past year.
AJ91 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.57% yearly.
The Revenue has been growing slightly by 0.69% in the past year.
Measured over the past years, AJ91 shows a quite strong growth in Revenue. The Revenue has been growing by 10.68% on average per year.
EPS 1Y (TTM)133.18%
EPS 3Y-22.65%
EPS 5Y10.57%
EPS Q2Q%501.79%
Revenue 1Y (TTM)0.69%
Revenue growth 3Y-14.46%
Revenue growth 5Y10.68%
Sales Q2Q%7.91%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AJ91.DE Yearly Revenue VS EstimatesAJ91.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 11.44, the valuation of AJ91 can be described as very reasonable.
Based on the Price/Earnings ratio, AJ91 is valued a bit cheaper than 80.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.54. AJ91 is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.44
Fwd PE N/A
AJ91.DE Price Earnings VS Forward Price EarningsAJ91.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AJ91 indicates a rather cheap valuation: AJ91 is cheaper than 90.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AJ91 indicates a rather cheap valuation: AJ91 is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.27
EV/EBITDA 3.72
AJ91.DE Per share dataAJ91.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.08
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

8

5. Dividend

5.1 Amount

AJ91 has a Yearly Dividend Yield of 6.20%, which is a nice return.
AJ91's Dividend Yield is rather good when compared to the industry average which is at 3.39. AJ91 pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, AJ91 pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.2%

5.2 History

The dividend of AJ91 has a limited annual growth rate of 4.52%.
Dividend Growth(5Y)4.52%
Div Incr Years1
Div Non Decr Years1
AJ91.DE Yearly Dividends per shareAJ91.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

AJ91 pays out 48.02% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of AJ91 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.02%
EPS Next 2YN/A
EPS Next 3YN/A
AJ91.DE Yearly Income VS Free CF VS DividendAJ91.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M
AJ91.DE Dividend Payout.AJ91.DE Dividend Payout, showing the Payout Ratio.AJ91.DE Dividend Payout.PayoutRetained Earnings

More info and screens

DOCCHECK AG

FRA:AJ91 (8/7/2025, 7:00:00 PM)

11.9

-0.1 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)09-20 2024-09-20
Earnings (Next)N/A N/A
Inst Owners8.86%
Inst Owner ChangeN/A
Ins Owners71.92%
Ins Owner ChangeN/A
Market Cap60.33M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.2%
Yearly Dividend0.5
Dividend Growth(5Y)4.52%
DP48.02%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 11.44
Fwd PE N/A
P/S 1.12
P/FCF 9.27
P/OCF 7.9
P/B 1.51
P/tB 1.51
EV/EBITDA 3.72
EPS(TTM)1.04
EY8.74%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.28
FCFY10.78%
OCF(TTM)1.51
OCFY12.66%
SpS10.61
BVpS7.91
TBVpS7.87
PEG (NY)N/A
PEG (5Y)1.08
Profitability
Industry RankSector Rank
ROA 9.09%
ROE 13.18%
ROCE 14.96%
ROIC 8.86%
ROICexc 17.58%
ROICexgc 17.72%
OM 12.33%
PM (TTM) 9.82%
GM 79.18%
FCFM 12.1%
ROA(3y)7.87%
ROA(5y)12.82%
ROE(3y)11.84%
ROE(5y)19.17%
ROIC(3y)9.31%
ROIC(5y)15.17%
ROICexc(3y)16.17%
ROICexc(5y)32.75%
ROICexgc(3y)16.36%
ROICexgc(5y)34.31%
ROCE(3y)15.72%
ROCE(5y)25.61%
ROICexcg growth 3Y-26.82%
ROICexcg growth 5Y-2.82%
ROICexc growth 3Y-26.26%
ROICexc growth 5Y-1.57%
OM growth 3Y-13.6%
OM growth 5Y-2.73%
PM growth 3Y-9.54%
PM growth 5Y0.26%
GM growth 3Y11.03%
GM growth 5Y-0.26%
F-Score6
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 45.88%
Cap/Sales 2.11%
Interest Coverage 250
Cash Conversion 83.94%
Profit Quality 123.15%
Current Ratio 2.74
Quick Ratio 2.5
Altman-Z 4.34
F-Score6
WACC6.81%
ROIC/WACC1.3
Cap/Depr(3y)102.11%
Cap/Depr(5y)131.26%
Cap/Sales(3y)5.41%
Cap/Sales(5y)5.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.18%
EPS 3Y-22.65%
EPS 5Y10.57%
EPS Q2Q%501.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.69%
Revenue growth 3Y-14.46%
Revenue growth 5Y10.68%
Sales Q2Q%7.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y86.96%
EBIT growth 3Y-26.09%
EBIT growth 5Y7.66%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.74%
FCF growth 3Y-1.99%
FCF growth 5Y54.46%
OCF growth 1Y1.69%
OCF growth 3Y-11.25%
OCF growth 5Y33.53%